These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 30790150)

  • 21. Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.
    Reed DR; Hall RD; Gentzler RD; Volodin L; Douvas MG; Portell CA
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e247-e250. PubMed ID: 30992232
    [No Abstract]   [Full Text] [Related]  

  • 22. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
    Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
    Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
    Singhi EK; Horn L
    Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Nishio M; Nakagawa K; Mitsudomi T; Yamamoto N; Tanaka T; Kuriki H; Zeaiter A; Tamura T
    Lung Cancer; 2018 Jul; 121():37-40. PubMed ID: 29858024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Novel
    Hillier K; Hughes A; Shamberger RC; Shusterman S; Perez-Atayde AR; Wassner AJ; Iafrate AJ; Dubuc A; Janeway KA; Rothenberg SM; Cox MC; Randolph GW; Wirth LJ; Tsai H; Church A; DuBois SG
    Thyroid; 2019 Nov; 29(11):1704-1707. PubMed ID: 31650892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
    Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
    Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful Alectinib Treatment for Carcinoma of Unknown Primary with
    Sugiyama K; Izumika A; Iwakoshi A; Nishibori R; Sato M; Shiraishi K; Hattori H; Nishimura R; Kitagawa C
    Curr Oncol; 2021 May; 28(3):1938-1945. PubMed ID: 34064158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
    Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
    Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report.
    Tateishi Y; Okudela K; Kawai S; Suzuki T; Umeda S; Matsumura M; Kioi M; Ohashi K
    Diagn Pathol; 2016 Nov; 11(1):132. PubMed ID: 27846861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role and targeting of anaplastic lymphoma kinase in cancer.
    Della Corte CM; Viscardi G; Di Liello R; Fasano M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
    Mol Cancer; 2018 Feb; 17(1):30. PubMed ID: 29455642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
    Tang Q; Li T; Ren F; Li X; Cao W; Yu H; Mao F; Cao C; Zu L; Xu S
    J Natl Compr Canc Netw; 2024 Feb; 22(2):. PubMed ID: 38364363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
    Santarpia M; Altavilla G; Rosell R
    Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
    Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
    Front Oncol; 2022; 12():761558. PubMed ID: 35237506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
    Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
    Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alectinib for advanced
    Ly AC; Olin JL; Smith MB
    Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
    Yoshida T; Hida T; Yatabe Y
    Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
    Ou SH; Ahn JS; De Petris L; Govindan R; Yang JC; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez SV; Mekhail T; Spira A; Bordogna W; Balas B; Morcos PN; Monnet A; Zeaiter A; Kim DW
    J Clin Oncol; 2016 Mar; 34(7):661-8. PubMed ID: 26598747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
    Lin J; Wang W; Lin J; Chen R; Cao Y
    J Cell Mol Med; 2022 Oct; 26(20):5326-5329. PubMed ID: 36102237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.